Will there be a large-dose trial? I imagine that’s going to be more difficult, as the weight-loss effect of GLP-1 means you cant include frail patients in your target group. And GLP-1 at high doses also has some unfavourable side-effects: nausea, vomiting, diarrhea, constipation.

Indeed, and it's literally not Ozempic but Rybelsus.

For reference in typical maintenance doses:

- Rybelsus (type-2 diabetes; oral semaglutide 14 mg/day; much less bioavailability)

- Wegovy (obesity; injectable semaglutide 2.4 mg/wk)

- Ozempic (type-2 diabetes; injectable semaglutide 1.0 mg/wk)